Our data suggested that the IRE1α kinase inhibitor APY29, which could block the upregulation of G-CSF and GM-CSF in glutamine deprived tumor cells in vitro, might be an option for future studies to reduce the mobilization and generation of MDSC. This evidence concerns the gene CSF2 and neoplasm.